Business Development

Partnering is a key part of Adagene’s growth strategy. We seek to partner to utilize Adagene’s unique skill set to develop therapeutics for new target classes that, if successful, will radically change the treatment paradigm within the target indication.

Adagene also plans to partner our lead antibody programs in combination trials. Due to the cross species reactive nature of the Adagene antibodies, we can take advantage of highly predictive models where we exhibit strong additive or synergistic behavior into the clinical setting.

For further information, please contact [email protected].

?Copyright-Adagene 2019
有没有推荐赚钱的软件 青海省11选5最新开奖体彩 天涯配资 青海西宁3形态一定牛 新基建大数据的股票 下载四川熊猫麻将 急速赛车计划app下载 广东11选55开奖 炒股平台哪个好 十一运夺金走势图开 赢翻网配资